September 24, 2020 -- Ideaya Biosciences has expanded its clinical trial collaboration and supply agreement with Pfizer for the combination study of IDE196, a protein kinase C inhibitor, and crizotinib, a c-MET inhibitor.
The new study will evaluate the combination therapy in patients with solid tumors that have GNAQ or GNA11 mutations, including metastatic uveal melanoma, skin melanoma, lung cancer, and colorectal cancer.
Ideaya is already evaluating IDE196 in combination with binimetinib. The clinical study for IDE196 and binimetinib began in June 2020 and is targeting to start evaluating the combination of IDE196 with crizotinib, for which Pfizer holds exclusive worldwide rights, in late 2020 to early 2021. Also, Ideaya is evaluating IDE196 as a monotherapy, which has recently entered phase II studies.
Ideaya and Pfizer have formed a joint development committee for clinical trials. Ideaya will sponsor the study and Pfizer will provide the crizotinib drug supply. If clinical data from the collaboration studies could be used to obtain regulatory approvals or label changes, Ideaya and Pfizer will enter into good faith negotiations to determine a regulatory submission strategy.